Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.35 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | PRKACA | P17612 | 1/20 | 0.35 |
| ▸ | LTK | P29376 | 1/20 | 0.35 |
| ▸ | GRK5 | P34947 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21879989 | 0.82 | NPSR1 (0.50) | NPSR1KDM4ECSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL21880088 | 0.81 | NPSR1 (0.39) | NPSR1KDM4ECSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL23931173 | 0.79 | GPR35 (0.36) | CSNK2A2CSNK2BCSNK2A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL23930858 | 0.79 | NPSR1 (0.34) | NPSR1KDM4EDAPK3JAK2PRKD3 | |
| SCHEMBL21879927 | 0.78 | NPSR1 (0.36) | NPSR1KDM4ECSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL23214476 | 0.78 | NPSR1 (0.36) | NPSR1KDM4ECSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL21879948 | 0.77 | NPSR1 (0.35) | NPSR1KDM4ECSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL19385591 | 0.74 | NPSR1 (0.50) | NPSR1KDM4ECSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL20477354 | 0.72 | ADCY10 (0.43) | KDM4EMAPK8PABPC1EIF4HRXFP1 | |
| SCHEMBL16210785 | 0.72 | NPSR1 (0.42) | NPSR1KDM4EDAPK3JAK2PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12065430-B2 | Indazole compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-08-20 | — | — | US | disclosed |
| EP-3871673-B1 | NOVEL INDAZOLE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2024-01-03 | — | — | EP | disclosed |
| US-20230183213-A1 | 5-MEMBERED HETEROARYL CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV | ASSEMBLY BIOSCIENCES, INC. | 2023-06-15 | — | — | US | disclosed |
| US-20230181536-A1 | ANTICANCER COMBINATION THERAPY WITH N-(1-ACRYLOYL-AZETIDIN-3-YL)-2-((1H-INDAZOL-3-YL)AMINO)METHYL)-1H-IMIDAZOLE-5-CARBOXAMIDE INHIBITOR OF KRAS-G12C | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-06-15 | — | — | US | disclosed |
| US-20230183213-A1 | 5-MEMBERED HETEROARYL CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV | ASSEMBLY BIOSCIENCES, INC. | 2023-06-15 | — | — | US | disclosed |
| US-20230183213-A1 | 5-MEMBERED HETEROARYL CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV | ASSEMBLY BIOSCIENCES, INC. | 2023-06-15 | — | — | US | disclosed |
| WO-2023069544-A1 | 5-MEMBERED HETEROARYL CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023069544-A1 | 5-MEMBERED HETEROARYL CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023069547-A1 | 5-MEMBERED HETEROARYL CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023069547-A1 | 5-MEMBERED HETEROARYL CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2021216656-A1 | 5-MEMBERED HETEROARYL CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV | ASSEMBLY BIOSCIENCES, INC. (US) | 2021-10-28 | — | — | WO | disclosed |
| WO-2021215545-A1 | ANTICANCER COMBINATION THERAPY WITH N-(1-ACRYLOYL-AZETIDIN-3-YL)-2-((1H-INDAZOL-3-YL)AMINO)METHYL)-1H-IMIDAZOLE-5-CARBOXAMIDE INHIBITOR OF KRAS-G12C | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-10-28 | — | — | WO | disclosed |
| WO-2021216656-A1 | 5-MEMBERED HETEROARYL CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV | ASSEMBLY BIOSCIENCES, INC. (US) | 2021-10-28 | — | — | WO | disclosed |
| US-10947203-B2 | 1,4,5-substituted 1,2,3-triazole analogues as antagonists of the pregnane X receptor | ST. JUDE CHILDREN'S RSEARCH HOSPITAL (US) | 2021-03-16 | — | — | US | disclosed |
| WO-2020085493-A1 | NOVEL INDAZOLE COMPOUND OR SALT THEREOF | 大鵬薬品工業株式会社 | 2020-04-30 | — | — | WO | disclosed |
| US-20200071281-A1 | 1,4,5-SUBSTITUTED 1,2,3-TRIAZOLE ANALOGUES AS ANTAGONISTS OF THE PREGNANE X RECEPTOR | ST JUDE CHILDREN?S RES HOSPITAL (US) | 2020-03-05 | — | — | US | disclosed |
| US-10550091-B2 | 1,4,5-substituted 1,2,3-triazole analogues as antagonists of the pregnane X receptor | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190077770-A1 | 1,4,5-SUBSTITUTED 1,2,3-TRIAZOLE ANALOGUES AS ANTAGONISTS OF THE PREGNANE X RECEPTOR | ST. JUDE CHILDREN'S RSEARCH HOSPITAL | 2019-03-14 | — | — | US | disclosed |
| WO-2017165139-A1 | 1,4,5-SUBSTITUTED 1,2,3-TRIAZOLE ANALOGUES AS ANTAGONISTS OF THE PREGNANE X RECEPTOR | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2017-09-28 | — | — | WO | disclosed |
| US-20130165472-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10550091-B2 | 1,4,5-substituted 1,2,3-triazole analogues as antagonists of the pregnane X receptor | NR5A1, CYP11B1, CYP3A5 | NPSR1 152/4885KDM4E 3569/4885CSNK2A2 2553/4885 |
| US-12065430-B2 | Indazole compound or salt thereof | RCOR3, H1-3, BICRA | NPSR1 2050/4885KDM4E 3013/4885CSNK2A2 649/4885 |
| US-20230183213-A1 | 5-MEMBERED HETEROARYL CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV | HCCS, HAVCR2, MAVS | NPSR1 4635/4885KDM4E 1967/4885CSNK2A2 738/4885 |
| US-20200071281-A1 | 1,4,5-SUBSTITUTED 1,2,3-TRIAZOLE ANALOGUES AS ANTAGONISTS OF THE PREGNANE X RECEPTOR | NR5A1, CYP11B1, CYP3A5 | NPSR1 152/4885KDM4E 3569/4885CSNK2A2 2553/4885 |
| US-20130165472-A1 | HETEROARYLS AND USES THEREOF | PIK3R4, VPS4B, PIK3C2A | NPSR1 2496/4885KDM4E 1283/4885CSNK2A2 737/4885 |
| US-10947203-B2 | 1,4,5-substituted 1,2,3-triazole analogues as antagonists of the pregnane X receptor | NR5A1, CYP11B1, CYP3A5 | NPSR1 166/4885KDM4E 3741/4885CSNK2A2 2598/4885 |
| US-20230181536-A1 | ANTICANCER COMBINATION THERAPY WITH N-(1-ACRYLOYL-AZETIDIN-3-YL)-2-((1H-INDAZOL-3-YL)AMINO)METHYL)-1H-IMIDAZOLE-5-CARBOXAMIDE INHIBITOR OF KRAS-G12C | KRAS, NRAS, HRAS | NPSR1 4865/4885KDM4E 3461/4885CSNK2A2 485/4885 |
| US-20190077770-A1 | 1,4,5-SUBSTITUTED 1,2,3-TRIAZOLE ANALOGUES AS ANTAGONISTS OF THE PREGNANE X RECEPTOR | NR5A1, CYP11B1, CYP3A5 | NPSR1 152/4885KDM4E 3569/4885CSNK2A2 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.